ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPRY

Shareholders who purchased shares of SPRY during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery. CLASS PERIOD: March 9, 2026 to June 24, 2026 DEADLINE: October 5, 2026 CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. ARS knew its timeline for CVS Caremark formulary and coverage approval decisions for neffy faced issues. The Company's commercialization plans would be impacted by this delay. Based on these facts, ARS's public statements were false and materially misleading throughout the class period. If you are a shareholder who suffered a loss, contact us to participate .